SRZN
Price
$15.63
Change
+$0.09 (+0.58%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
138.17M
Intraday BUY SELL Signals
UPB
Price
$27.00
Change
+$1.99 (+7.96%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
1.57B
Intraday BUY SELL Signals
Interact to see
Advertisement

SRZN vs UPB

Header iconSRZN vs UPB Comparison
Open Charts SRZN vs UPBBanner chart's image
Surrozen
Price$15.63
Change+$0.09 (+0.58%)
Volume$1.98K
Capitalization138.17M
Upstream Bio
Price$27.00
Change+$1.99 (+7.96%)
Volume$6.41K
Capitalization1.57B
SRZN vs UPB Comparison Chart in %
SRZN
Daily Signal:
Gain/Loss:
UPB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
SRZN vs. UPB commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SRZN is a StrongBuy and UPB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (SRZN: $15.65 vs. UPB: $25.01)
Brand notoriety: SRZN and UPB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SRZN: 102% vs. UPB: 105%
Market capitalization -- SRZN: $138.17M vs. UPB: $1.57B
SRZN [@Biotechnology] is valued at $138.17M. UPB’s [@Biotechnology] market capitalization is $1.57B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SRZN’s FA Score shows that 1 FA rating(s) are green whileUPB’s FA Score has 0 green FA rating(s).

  • SRZN’s FA Score: 1 green, 4 red.
  • UPB’s FA Score: 0 green, 5 red.
According to our system of comparison, SRZN is a better buy in the long-term than UPB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SRZN’s TA Score shows that 5 TA indicator(s) are bullish while UPB’s TA Score has 4 bullish TA indicator(s).

  • SRZN’s TA Score: 5 bullish, 5 bearish.
  • UPB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both SRZN and UPB are a good buy in the short-term.

Price Growth

SRZN (@Biotechnology) experienced а -2.28% price change this week, while UPB (@Biotechnology) price change was -13.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
UPB($1.57B) has a higher market cap than SRZN($138M). UPB YTD gains are higher at: 52.129 vs. SRZN (9.024). SRZN has higher annual earnings (EBITDA): -24.83M vs. UPB (-121.42M). UPB has more cash in the bank: 394M vs. SRZN (90.4M). UPB has less debt than SRZN: UPB (1.56M) vs SRZN (7.51M). SRZN has higher revenues than UPB: SRZN (12.6M) vs UPB (2.72M).
SRZNUPBSRZN / UPB
Capitalization138M1.57B9%
EBITDA-24.83M-121.42M20%
Gain YTD9.02452.12917%
P/E RatioN/AN/A-
Revenue12.6M2.72M463%
Total Cash90.4M394M23%
Total Debt7.51M1.56M481%
TECHNICAL ANALYSIS
Technical Analysis
SRZNUPB
RSI
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 6 days ago
70%
Momentum
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
87%
MACD
ODDS (%)
Bullish Trend 6 days ago
90%
Bullish Trend 6 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 6 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
86%
Bullish Trend 9 days ago
89%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
84%
Bearish Trend 6 days ago
77%
Aroon
ODDS (%)
Bearish Trend 6 days ago
85%
Bullish Trend 6 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
SRZN
Daily Signal:
Gain/Loss:
UPB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OPGIX50.68N/A
N/A
Invesco Global Opportunities A
KMKYX74.94N/A
N/A
Kinetics Market Opportunities Inst
NFACX36.32N/A
N/A
Neuberger Berman Focus C
HBLSX15.28N/A
N/A
Hartford Balanced Income R4
NBMRX28.65N/A
N/A
Neuberger Berman M/C Intrinsic Val R6

SRZN and

Correlation & Price change

A.I.dvisor tells us that SRZN and KMSTF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SRZN and KMSTF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRZN
1D Price
Change %
SRZN100%
-2.95%
KMSTF - SRZN
27%
Poorly correlated
N/A
UPB - SRZN
27%
Poorly correlated
-13.70%
DWTX - SRZN
27%
Poorly correlated
-2.05%
CRBP - SRZN
26%
Poorly correlated
-4.42%
IPSC - SRZN
26%
Poorly correlated
-2.62%
More

UPB and

Correlation & Price change

A.I.dvisor indicates that over the last year, UPB has been loosely correlated with CRVS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if UPB jumps, then CRVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UPB
1D Price
Change %
UPB100%
-13.70%
CRVS - UPB
42%
Loosely correlated
-5.29%
IPSC - UPB
42%
Loosely correlated
-2.62%
IDYA - UPB
42%
Loosely correlated
-1.75%
SYRE - UPB
41%
Loosely correlated
-0.91%
CRNX - UPB
41%
Loosely correlated
-0.53%
More